Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13399230 | 0.94 | PTPN1 (0.33) | PTPN1KMT2AATMFFAR1FFAR4 | |
| SCHEMBL12603643 | 0.89 | PTPN1 (0.33) | PTPN1KMT2AATMFFAR1FFAR4 | |
| SCHEMBL98141 | 0.89 | KMT2A (0.34) | PTPN1KMT2AATMFFAR1FFAR4 | |
| SCHEMBL12603641 | 0.84 | FGFR1 (0.35) | PTPN1KMT2AATMFFAR1FFAR4 | |
| SCHEMBL13399680 | 0.83 | CYP1A2 (0.41) | SMN1; SMN2MAPT | |
| SCHEMBL13399575 | 0.82 | MAPT (0.37) | ATMMAPT | |
| SCHEMBL13399660 | 0.80 | CASP3 (0.45) | KMT2AMEN1SMN1; SMN2MAPT | |
| SCHEMBL13399681 | 0.79 | KMT2A (0.33) | PTPN1KMT2AATMFFAR1FFAR4 | |
| SCHEMBL10169610 | 0.78 | SCN8A (0.34) | KMT2AATMFFAR4MEN1MAPT | |
| SCHEMBL12603650 | 0.77 | MGLL (0.37) | PTPN1KMT2AFFAR1FFAR4MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541157-B2 | Resist composition, method of forming resist pattern, compound and acid generator including the same | TOKYO OHKA KOGYO CO., LTD. (JP) | 2013-09-24 | — | — | US | disclosed |
| US-20100081088-A1 | RESIST COMPOSITION, METHOD OF FORMING RESIST PATTERN, COMPOUND AND ACID GENERATOR INCLUDING THE SAME | TOKYO OHKA KOGYO CO., LTD. (JP) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081088-A1 | RESIST COMPOSITION, METHOD OF FORMING RESIST PATTERN, COMPOUND AND ACID GENERATOR INCLUDING THE SAME | ASIC1, RER1, GRIN1 | PTPN1 4335/4885KMT2A 2329/4885ATM 2353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.